Epistem provides a service that offers orthotopic models of Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Lung, Ovarian and Prostate cancer. Cell lines are lentivirally transduced with luciferase and GFP, enabling disease progression and response to novel therapeutic agents to be monitored longitudinally using Epistem's state-of-the-art imaging facility. All of our models are fully complemented by our range of in vitro and ex vivo assays, as well as our comprehensive FACS, histology and biomarker analytical services.
Leukemic Orthotopic Models:
Models use either direct intrafemoral or intravenous injection of luc+ human leukemic cell lines showing consistent engraftment and development of disease in the bone marrow and peripheral blood.
Acute Myeloid Leukemia (AML) is the most common form of adult leukemia and is characterised by clonal proliferation of myeloid precursors. Acute Lymphoblastic Leukemia (ALL) predominantly affects children and is characterised by the overproduction and lack of differentiation of lymphocytes.
Solid Tumour Orthotopic Models:
Epistem also offers validated orthotopic models of lung, ovarian and prostate cancer, and we are constantly expanding our portfolio. We also offer a bespoke service for new model development, using either commercially available cell lines, or our ability to transduce cell lines of your choice.
Epistem's orthotopic models are fully validated with standard of care agents and can be used to provide data including:
- Target validation
- Efficacy of novel therapeutic agents
- In-life assessments for pK/pD analysis